Eli Lilly allies itself with Alzheimer's institute in phase III dementia drug trials
Banner Alzheimer's Institute will assist Eli Lilly in its phase III study of the company's Alzheimer's treatment, donanemab.
BY RITZAU FINANS AND ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Eli Lilly has announced a collaboration with Banner Alzheimer's Institute, which specializes in early identification and tracking of the disease, over a phase III trial of its drug donanemab.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly acquires biotech firm in new insulin venture
For subscribers
FDA changes prescribing information for new Alzheimer's drug
For subscribers
.jpg)
.jpg&w=384&q=75)
